170 related articles for article (PubMed ID: 15616412)
1. Comparison of cardiovascular risk factors and drug use in 14,544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease.
Bongard V; Cambou JP; Lezorovcz A; Ferrères J; Vahanan A; Jullen G; Coppe G; Guerllot M; Herrmann MA; Mas JL
Eur J Cardiovasc Prev Rehabil; 2004 Oct; 11(5):394-402. PubMed ID: 15616412
[TBL] [Abstract][Full Text] [Related]
2. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
Cambou JP; Ferrieres J; Grenier O; Boka G; Cantet C; Leizorovicz A
Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
[TBL] [Abstract][Full Text] [Related]
3. [Prevalence and management of patients with a prior history of atherothrombotic disease in primary care in France. Results of the ECLAT1 survey].
Bóngard V; Cambou JP; Coppe G; Jullien G; Vahanian A; Mas JL
Arch Mal Coeur Vaiss; 2003 Sep; 96(9):833-40. PubMed ID: 14571635
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic.
Ness J; Aronow WS; Newkirk E; McDanel D
J Gerontol A Biol Sci Med Sci; 2005 Feb; 60(2):255-7. PubMed ID: 15814871
[TBL] [Abstract][Full Text] [Related]
5. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
[TBL] [Abstract][Full Text] [Related]
6. [Risk factors management in 5708 ambulatory patients suffering from peripheral vascular disease followed in urban practices].
Dedola M; Godoi E; Coppé G; Cambou JP; Cantet C; Mas JL; Guérillot M; Vahanian A; Herrman MA; Jullien G; Leizorovicz A; Boccalon H
Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1179-86. PubMed ID: 16435595
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
Winkel TA; Hoeks SE; Schouten O; Zeymer U; Limbourg T; Baumgartner I; Bhatt DL; Steg PG; Goto S; Röther J; Cacoub PP; Verhagen HJ; Bax JJ; Poldermans D
Eur J Vasc Endovasc Surg; 2010 Jul; 40(1):9-16. PubMed ID: 20385507
[TBL] [Abstract][Full Text] [Related]
8. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Hacke W
Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry.
Khan S; Flather M; Mister R; Delahunty N; Fowkes G; Bradbury A; Stansby G
Eur J Vasc Endovasc Surg; 2007 Apr; 33(4):442-50. PubMed ID: 17196851
[TBL] [Abstract][Full Text] [Related]
10. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry.
Alberts MJ; Bhatt DL; Mas JL; Ohman EM; Hirsch AT; Röther J; Salette G; Goto S; Smith SC; Liau CS; Wilson PW; Steg PG;
Eur Heart J; 2009 Oct; 30(19):2318-26. PubMed ID: 19720633
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Blinc A; Poredos P
Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.
Bianchi C; Montalvo V; Ou HW; Bishop V; Abou-Zamzam AM
Ann Vasc Surg; 2007 Mar; 21(2):163-6. PubMed ID: 17349357
[TBL] [Abstract][Full Text] [Related]
13. Rationale for the use of platelet aggregation inhibitors in PAD patients.
Agnelli G
Vasc Med; 2001; 6(3 Suppl):13-5. PubMed ID: 11789961
[TBL] [Abstract][Full Text] [Related]
14. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
Chi YW; Jaff MR
Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
[TBL] [Abstract][Full Text] [Related]
15. Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.
Kundhal KK; Chin SL; Harrison L; Nowacki B; Doobay B; Titley J; Ciná C; Anand SS
Can J Cardiol; 2007 Apr; 23(5):357-61. PubMed ID: 17440640
[TBL] [Abstract][Full Text] [Related]
16. The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit.
Sturm JW; Davis SM; O'Sullivan JG; Vedadhaghi ME; Donnan GA
Med J Aust; 2002 Apr; 176(7):312-6. PubMed ID: 12013322
[TBL] [Abstract][Full Text] [Related]
17. Role of antiplatelet drugs in the prevention of cardiovascular events.
Tendera M; Wojakowski W
Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
[TBL] [Abstract][Full Text] [Related]
18. Atherothrombosis: a major health burden.
Leys D
Cerebrovasc Dis; 2001; 11 Suppl 2():1-4. PubMed ID: 11316915
[TBL] [Abstract][Full Text] [Related]
19. Comparison of hypertension management after stroke and myocardial infarction: results from ECLAT1--a French nationwide study.
Amar J; Cambou JP; Touzé E; Bongard V; Jullien G; Vahanian A; Coppé G; Mas JL;
Stroke; 2004 Jul; 35(7):1579-83. PubMed ID: 15155960
[TBL] [Abstract][Full Text] [Related]
20. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
